Enlivex Ltd. (Nasdaq: ENLV), a clinical-stage quality longevity company, announced on March 24, 2026, a $21 million debt financing round. The Lind Partners, a New York-based institutional fund manager, provided the debt financing. Enlivex develops Allocetra, an immunotherapy targeting inflammatory conditions associated with aging, primarily age-related osteoarthritis. The company also operates a prediction markets treasury strategy centered on the RAIN protocol.
Funding Overview
Enlivex closed a $21 million debt financing agreement with The Lind Partners on March 23, 2026. The convertible note carries a fixed conversion price of $2.69175 per ordinary share, representing a 264% premium to the Nasdaq closing price on March 20, 2026. Net proceeds totaled approximately $18.7 million before offering expenses. H.C. Wainwright & Co. served as the placement agent for the debt financing. In the broader digital asset and startup ecosystem, similar capital movements continue to emerge, as Kash raises $2M, highlighting sustained investor interest across both fintech and Web3-driven models.
Enlivex exercised an option to acquire 3,030,303,030 RAIN tokens at $0.0033 per token, totaling $10 million. This price reflected a 62% discount to the RAIN token’s closing price on March 22, 2026. RAIN tokens have traded in the range of $0.008 to $0.01 in recent weeks.
The Rain Foundation extended Enlivex’s option to acquire up to an additional 272,121,212,121 RAIN tokens at $0.0033 per token. The extension shifts the expiration from November 30, 2026, to December 31, 2027.
Enlivex’s Board of Directors approved a $20 million share repurchase program for its outstanding ordinary shares. Repurchases may occur through open market transactions, privately negotiated deals, or Rule 10b5-1 trading plans, subject to regulatory requirements. The program has no expiration date and may be modified, suspended, or terminated at any time.
About the Company
Enlivex Ltd., based in Nes-Ziona, Israel, is a quality longevity company powered by a prediction markets treasury. The company advances Allocetra, a clinical-stage immunotherapy designed to treat inflammatory conditions linked to aging.
Enlivex pairs its longevity research with treasury operations focused on decentralized prediction markets. Its treasury strategy centers on the RAIN protocol, the leading decentralized prediction markets infrastructure on the Arbitrum blockchain. The Rain Foundation independently oversees the RAIN protocol.
Shai Novik, Executive Chairman of Enlivex, stated that the actions support execution of the company’s prediction markets treasury strategy. Oren Hershkovitz, CEO of Enlivex, noted that the share repurchase reflects a view that ENLV shares trade at a discount to the market value of the company’s treasury and related assets.
Market Context
RAIN serves as the native token for the Rain decentralized prediction markets protocol on Arbitrum. The protocol enables decentralized prediction markets infrastructure. Enlivex’s treasury accumulation includes RAIN tokens acquired at fixed prices below recent market levels. The extended option provides Enlivex with additional runway for token purchases through 2027.
The debt financing and token acquisition align with Enlivex’s dual-engine model, combining clinical immunotherapy development with exposure to prediction markets growth. Share repurchases under the program will depend on factors including share price, trading volume, and market conditions.
Disclaimer: Cryip's content is strictly for educational and informational purposes and does not constitute financial, legal, or investment advice. Cryptocurrency involves significant risk, and readers assume full responsibility for their own financial decisions. Asset references are never endorsements.
To make complex crypto topics accessible to readers at all experience levels, our team uses AI tools strictly to refine language, correct grammar, and simplify terminology. AI is never used to draft facts, source information, or form conclusions. Every article is fact-checked and approved by a human editor before publication. Read our full AI Use & Content Policy.
